Cargando…
P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642064/ http://dx.doi.org/10.1097/01.HS9.0000891016.06930.34 |
| _version_ | 1784826223282618368 |
|---|---|
| author | Mei, Matthew Palmer, Joycelynne Maddocks, Kami Martin, Peter Tsai, Ni-Chun Smith, Eileen Popplewell, Leslie Armenian, Saro Shouse, Geoffrey Chen, Robert Kwak, Larry Rosen, Steven T. Forman, Stephen Bond, David Herrera, Alex F. |
| author_facet | Mei, Matthew Palmer, Joycelynne Maddocks, Kami Martin, Peter Tsai, Ni-Chun Smith, Eileen Popplewell, Leslie Armenian, Saro Shouse, Geoffrey Chen, Robert Kwak, Larry Rosen, Steven T. Forman, Stephen Bond, David Herrera, Alex F. |
| author_sort | Mei, Matthew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9642064 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96420642022-11-14 P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma Mei, Matthew Palmer, Joycelynne Maddocks, Kami Martin, Peter Tsai, Ni-Chun Smith, Eileen Popplewell, Leslie Armenian, Saro Shouse, Geoffrey Chen, Robert Kwak, Larry Rosen, Steven T. Forman, Stephen Bond, David Herrera, Alex F. Hemasphere Relapsed/Refractory Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9642064/ http://dx.doi.org/10.1097/01.HS9.0000891016.06930.34 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Relapsed/Refractory Mei, Matthew Palmer, Joycelynne Maddocks, Kami Martin, Peter Tsai, Ni-Chun Smith, Eileen Popplewell, Leslie Armenian, Saro Shouse, Geoffrey Chen, Robert Kwak, Larry Rosen, Steven T. Forman, Stephen Bond, David Herrera, Alex F. P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma |
| title | P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma |
| title_full | P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma |
| title_fullStr | P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma |
| title_full_unstemmed | P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma |
| title_short | P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma |
| title_sort | p112: phase ii trial of brentuximab vedotin plus ibrutinib in relapsed/refractory hodgkin lymphoma |
| topic | Relapsed/Refractory |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642064/ http://dx.doi.org/10.1097/01.HS9.0000891016.06930.34 |
| work_keys_str_mv | AT meimatthew p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT palmerjoycelynne p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT maddockskami p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT martinpeter p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT tsainichun p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT smitheileen p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT popplewellleslie p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT armeniansaro p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT shousegeoffrey p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT chenrobert p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT kwaklarry p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT rosenstevent p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT formanstephen p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT bonddavid p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma AT herreraalexf p112phaseiitrialofbrentuximabvedotinplusibrutinibinrelapsedrefractoryhodgkinlymphoma |